D228
D228 is an orally active antiinflammatory agent. D228 reduces ConA induced T lymphocyte cell proliferation (IC50: 42.85 μM) and LPS induced B lymphocyte cell proliferation (IC50: 3.15 μM). D228 is effective against inflammatory bowel disease (IBD). D228 alleviates the DSS -induced inflammation response in the IBD model by downregulating the MyD88/TRAF6/p38 signaling[1].
Product Specifications
CAS Number
2676188-98-8
UNSPSC
12352005
Target
MyD88; p38 MAPK
Type
Reference compound
Related Pathways
Immunology/Inflammation; MAPK/ERK Pathway
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/d228.html
Purity
99.77
Solubility
DMSO : 50 mg/mL (ultrasonic)
Smiles
CC1=C(C(/C(O1)=C(C)\C)=O)O[C@H]2[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)O2
Molecular Formula
C22H28O12
Molecular Weight
484.45
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Recombinant Klebsiella Pneumoniae argO Protein (aa 1-211) (strain ATCC 700721 / MGH 78578)
Human Carbohyde sulfotransferase 8 (CHST8) ELISA kit